TY - JOUR AB - The present study aimed to investigate the predictive value of pretreatment fibrinogen (FIB) levels in patients with cancer who received immunotherapy as a second‑line treatment. A total of 61 patients with stage III‑IV cancer were included. The cut‑off value of FIB for predicting overall survival (OS) was determined by receiver operating characteristic curve analysis. The prognostic value of pretreatment FIB on progression‑free survival (PFS) and OS was determined by univariate and multivariate analyses. Based on a cut‑off point of 3.47 g/l, patients were divided into low pretreatment FIB (<3.47 g/l) and high pretreatment FIB (≥3.47 g/l) groups. A high pretreatment FIB level was more common in older patients (P=0.03). Kaplan‑Meier analysis showed that patients with high pretreatment FIB levels had shorter PFS and OS times than patients with low FIB levels (P<0.05). In multivariate analysis, pretreatment FIB was an independent prognostic factor for OS [hazard ratio (HR), 6.06; 95% CI, 2.01‑18.28; P<0.01] and OS from the initiation of second‑line treatment (HR, 3.69; 95% CI, 1.28‑10.63; P=0.02). Overall, FIB is associated with survival outcome in patients with cancer who are administered immunotherapy as a second‑line treatment. AD - Department of Oncology, Hainan Hospital of People's Liberation Army General Hospital, Sanya, Hainan 572013, P.R. China Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China AU - Xu,Rui AU - Yang,Tao AU - Yan,Bing AU - You,Junhao AU - Li,Fang AU - Zuo,Qiang DA - 2023/06/01 DO - 10.3892/ol.2023.13855 IS - 6 JO - Oncol Lett KW - immune checkpoint inhibitors immunotherapy pan‑cancer fibrinogen prognostic factor PY - 2023 SN - 1792-1074 1792-1082 SP - 269 ST - Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment T2 - Oncology Letters TI - Pretreatment fibrinogen levels are associated with survival outcome in patients with cancer using immunotherapy as a second‑line treatment UR - https://doi.org/10.3892/ol.2023.13855 VL - 25 ER -